Three therapies, when used in combination, may slow advanced melanoma, according to a new study led by researchers at UCLA. The study, published online ahead of print in the journal Nature Medicine (June 6, 2019) showed that the combination of dabrafenib, trametinib, and pembrolizaumab can slow the growth of advanced melanoma cancer cells.
Skin cancer patients with a history of smoking have a significantly lower survival rate than skin cancer patients who do not smoke. Smoking cigarettes decreases survival rate in melanoma patients by 40 per cent according to a new study published by the medical journal Cancer Research (Feb. 17, 2019).
Patients in the United States who live in a state with a higher incidence of melanoma are more likely to survive the disease. Conversely, Americans who live in a state with a lower incidence of melanoma are less likely to survive the disease. Researchers believe that this seeming contradiction might be a result of better detection in more well-funded regions leading to better outcomes.